[A20-06] Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71
Last updated 20.02.2020
Project no.:
A20-06
Commission:
Commission awarded on 07.01.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Indication:
Cystic fibrosis in patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene
Result of dossier assessment:
Conclusion of dossier assessment A19-71 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-71 | Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.